OBJECTIVES: We hypothesized that @entity117 ( @entity1281 ) might alter the beneficial effect of beta-blockers on left ventricular ejection fraction (LVEF) in @entity1 with @entity712 . BACKGROUND: @entity117 blunts the vasodilation caused by both @entity1289 ( @entity1289 ) inhibitors and beta-blockers in @entity101 @entity1 and in @entity1 with @entity712 . Several studies suggest that @entity1281 also blunts some of beneficial effects of @entity1289 inhibitors on mortality in @entity1 with @entity712 . To our knowledge, there have been no data evaluating the possible interaction of @entity1281 and beta-blockers on left ventricular remodeling in @entity1 with @entity712 . METHODS: We retrospectively evaluated @entity1 entered into the Multicenter Oral @entity1405 Heart failure Assessment (MOCHA) trial, a 6-month, double-blind, randomized, placebo-controlled, multicenter, dose-response evaluation of @entity1405 in @entity1 with chronic stable symptomatic @entity712 . Multivariate analysis was performed to determine if @entity117 independently influenced the improvement in LVEF. RESULTS: Over all randomized @entity1 (n = 293), LVEF improved 8.2 +/- 0.8 ejection fraction (EF) units in @entity1281 nonusers and 4.5 +/- 0.7 EF units in @entity1281 users (p = 0.005). In subjects randomized to treatment with @entity1405 (n = 231), LVEF improved 9.5 +/- 0.9 EF units in @entity1281 nonusers and 5.8 +/- 0.8 EF units in @entity1281 users (p = 0.02). In subjects randomized to treatment with placebo (n = 62), LVEF improved 2.8 +/- 1.2 EF units in @entity1281 nonusers and 0.5 +/- 1.4 EF units in @entity1281 users (p = 0.20). @entity117 did not significantly affect the heart rate or systolic blood pressure response in either the placebo or @entity1405 groups. The effect of @entity1281 became more significant on multivariate analysis. The change in LVEF was also influenced by @entity1405 dose, etiology of @entity712 , baseline heart rate, EF and @entity1229 use. The detrimental effect of @entity1281 on the improvement in LVEF was dose-related and was present in both placebo and @entity1405 groups, although the effect was statistically significant only in the much larger @entity1405 group. CONCLUSIONS: @entity117 significantly affects the changes in LVEF over time in @entity1 with @entity712 and @entity299 treated with @entity1405 . The specific mechanism(s) underlying this interaction are unknown and further studies are needed to provide additional understanding of the molecular basis of factors influencing reverse remodeling in @entity1 with @entity712 .

XXXX impairs reverse myocardial remodeling in @entity1 with @entity712 treated with beta-blockers.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['chronic heart failure', 'heart failure'] @entity1289 :: ('1636', 'Gene') :: ['ACE', 'angiotensin-converting enzyme'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin'] @entity1405 :: ('MESH:C043211', 'Chemical') :: ['carvedilol', 'Carvedilol'] @entity299 :: ('MESH:D006331', 'Disease') :: ['systolic dysfunction'] @entity1281 :: ('CHEBI:15365', 'Chemical') :: ['ASA'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['coumadin']
@entity117 :: (MESH:D001241,Chemical) :: ['Aspirin']
